Get the Stockscreener App
13.87
7.94%
1.02
Regenxbio Inc stock is traded at $13.87, with a volume of 604.25K.
It is up +7.94% in the last 24 hours and up +19.57% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$12.85
Open:
$12.9
24h Volume:
604.25K
Relative Volume:
1.03
Market Cap:
$702.14M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-2.6369
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
+5.40%
1M Performance:
+19.57%
6M Performance:
+35.98%
1Y Performance:
+59.06%
1-Day Range:
$12.69
$14.24
1-Week Range:
$12.61
$14.24
52-Week Range:
$5.035
$14.24
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
13.87 | 650.51M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
(RGNX) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
REGENXBIO (NASDAQ:RGNX) Reaches New 52-Week HighShould You Buy? - MarketBeat
Wet Age-Related Macular Degeneration Market Growth - openPR.com
Voss Capital LP Boosts Stock Holdings in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. $RGNX is 22NW LP's 5th Largest Position - MarketBeat
Will REGENXBIO Inc. (RB0) stock announce special dividend2025 Major Catalysts & Real-Time Volume Spike Alerts - Newser
What insider trading reveals about REGENXBIO Inc. stockJuly 2025 Snapshot & Smart Allocation Stock Tips - Newser
Why global investors buy REGENXBIO Inc. (RB0) stock2025 Market WrapUp & Safe Capital Allocation Plans - Newser
Will REGENXBIO Inc. (RB0) stock profit from fiscal stimulus2025 Big Picture & Safe Entry Zone Identification - Newser
Can REGENXBIO Inc. stock resist market sell offsQuarterly Profit Review & Technical Pattern Based Signals - Newser
Is REGENXBIO Inc. stock resilient to inflationGold Moves & Fast Exit Strategy with Risk Control - Newser
JPMorgan Chase & Co. Sells 512,318 Shares of REGENXBIO Inc. $RGNX - MarketBeat
Will REGENXBIO Inc. (RB0) stock see valuation expansionWeekly Trade Analysis & Reliable Trade Execution Plans - Newser
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
Commercial Lessons From The Cell And Gene Therapy Frontlines - Citeline News & Insights
How (RGNX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
26,773 Shares in REGENXBIO Inc. $RGNX Bought by Rockefeller Capital Management L.P. - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Gainers Report: Is REGENXBIO Inc. stock a contrarian buyJuly 2025 Summary & Risk Managed Trade Strategies - moha.gov.vn
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript - The Globe and Mail
Regenxbio files $300M mixed securities shelf - MSN
Transcript : REGENXBIO Inc. Presents at Stifel 2025 Healthcare Conference, Nov-11-2025 01 - marketscreener.com
Regenxbio files $300M mixed shelf offering - MSN
Regenxbio (RGNX) Files for $300M Securities Offering - GuruFocus
Regenxbio files for mixed shelf of up to $300 millionSEC filing - marketscreener.com
[S-3] REGENXBIO Inc. Shelf Registration Statement | RGNX SEC FilingForm S-3 - Stock Titan
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet? - 富途牛牛
REGENXBIO to Participate in Upcoming Investor Conference - PR Newswire
Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN
Brokers Set Expectations for REGENXBIO FY2026 Earnings - MarketBeat
REGENXBIO (NASDAQ:RGNX) Given Buy Rating at Chardan Capital - MarketBeat
RGNX S-8及美國證券交易委員會申報文件 - Yahoo 財經
Chardan Capital Maintains Buy Rating for RGNX with $52 Price Tar - GuruFocus
Is REGENXBIO Inc. (RB0) stock safe for risk averse investors2025 Earnings Impact & Precise Swing Trade Alerts - newser.com
Will REGENXBIO Inc. (RB0) stock profit from AI boomJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - newser.com
How REGENXBIO Inc. stock responds to policy changes2025 Investor Takeaways & Long-Term Growth Portfolio Plans - newser.com
Visualizing REGENXBIO Inc. stock with heatmapsWeekly Trade Recap & Intraday High Probability Alerts - newser.com
Reversal indicators forming on REGENXBIO Inc. stock2025 Breakouts & Breakdowns & Intraday High Probability Alerts - newser.com
Trading Systems Reacting to (RGNX) Volatility - news.stocktradersdaily.com
Will REGENXBIO Inc. stock split again soonTrade Ideas & Precise Buy Zone Tips - newser.com
What data driven models say about REGENXBIO Inc.’s futurePortfolio Value Summary & Consistent Income Trade Recommendations - newser.com
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):